

# Sophie Poty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5027064/publications.pdf>

Version: 2024-02-01

16  
papers

540  
citations

687363

13  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

896  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. <i>Pharmaceutics</i> , 2021, 13, 980.   | 4.5  | 14        |
| 2  | <sup>89</sup> Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following <sup>131</sup> I- and <sup>125</sup> I-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. <i>Theranostics</i> , 2020, 10, 5802-5814. | 10.0 | 15        |
| 3  | Trastuzumab gold-conjugates: synthetic approach and <i>in vitro</i> evaluation of anticancer activities in breast cancer cell lines. <i>Chemical Communications</i> , 2019, 55, 1394-1397.  | 4.1  | 24        |
| 4  | Innovative Magnetic Nanoparticles for PET/MRI Bimodal Imaging. <i>ACS Omega</i> , 2019, 4, 2637-2648.   | 3.5  | 46        |
| 5  | A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , 2019, 71, 32-38.   | 0.6  | 34        |
| 6  | Leveraging Bioorthogonal Click Chemistry to Improve <sup>225</sup> Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 868-880.  | 7.0  | 55        |
| 7  | <sup>131</sup> I-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies”Part 2. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1020-1027.   | 5.0  | 72        |
| 8  | The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of <sup>225</sup> Ac-labelled radioimmunoconjugates. <i>Chemical Communications</i> , 2018, 54, 2599-2602.  | 4.1  | 33        |
| 9  | Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy”Model, vector, and radionuclide selection. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 611-635.                                   | 1.0  | 24        |
| 10 | <sup>131</sup> I-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies”Part 1. <i>Journal of Nuclear Medicine</i> , 2018, 59, 878-884.   | 5.0  | 131       |
| 11 | MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET. <i>Dalton Transactions</i> , 2017, 46, 14659-14668.   | 3.3  | 15        |
| 12 | AMD3100: A Versatile Platform for CXCR4 Targeting <sup>68</sup> Ga-Based Radiopharmaceuticals. <i>Bioconjugate Chemistry</i> , 2016, 27, 752-761.   | 3.6  | 21        |
| 13 | MA-NOTMP: A Triazacyclononane Trimethylphosphinate Based Bifunctional Chelator for Gallium Radiolabelling of Biomolecules. <i>ChemMedChem</i> , 2015, 10, 1475-1479.  | 3.2  | 10        |
| 14 | New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. <i>Dalton Transactions</i> , 2015, 44, 5004-5016.   | 3.3  | 28        |
| 15 | New imaging agents targeting chemokine receptor CXCR4 for PET/SPECT and MRI. <i>EJNMMI Physics</i> , 2014, 1, A81.  | 2.7  | 2         |
| 16 | Efficient Synthesis of 1,4,7-triazacyclononane and 1,4,7-triazacyclononane-based Bifunctional Chelators for Bioconjugation. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 7831-7838.   | 2.4  | 16        |